MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

568.45 +10.44 (+1.87%)
Streaming Delayed Price Updated: 10:58 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗
Both stocks are pretty risky, but one of them more so than the other. 
Via The Motley Fool
News headline image
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? ↗
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off? 
Via The Motley Fool
News headline image
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
News headline image
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock ↗
This biotech just got clearance to dive into a deep ocean of a market. 
Via The Motley Fool
News headline image
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? ↗
The mid-cap biotech has succeeded where many others failed. 
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
Via Investor Brand Network
News headline image
Madrigal Pharmaceuticals: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? ↗
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring ↗
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease.... 
Via Benzinga
News headline image
Why Is Geron (GERN) Stock Up 94% Today? ↗
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. 
Via InvestorPlace
News headline image
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
News headline image
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today ↗
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH ↗
The company hopes to be the first to the finish line with a treatment for MASH. 
Via Investor's Business Daily
News headline image
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Good news could be in store for all three of these drugmakers. 
Via The Motley Fool
News headline image
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
News headline image
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? ↗
This business could be on the cusp of making medical history. 
Via The Motley Fool
News headline image
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
News headline image
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street ↗
The company might have a bright future, but is now the right time to buy shares? 
Via The Motley Fool
News headline image
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug ↗
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story